Literature DB >> 23507702

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.

Peter M van Koetsveld1, Giovanni Vitale, Richard A Feelders, Marlijn Waaijers, Diana M Sprij-Mooij, Ronald R de Krijger, Ernst-Jan M Speel, Johannes Hofland, Steven W J Lamberts, Wouter W de Herder, Leo J Hofland.   

Abstract

Adrenocortical carcinoma (ACC) is an aggressive tumor with very poor prognosis. Novel medical treatment opportunities are required. We investigated the effects of interferon-β (IFN-β), alone or in combination with mitotane, on cell growth and cortisol secretion in primary cultures of 13 human ACCs, three adrenal hyperplasias, three adrenal adenomas, and in two ACC cell lines. Moreover, the interrelationship between the effects of IGF2 and IFN-β was evaluated. Mitotane inhibited cell total DNA content/well (representing cell number) in 7/11 (IC50: 38±9.2 μM) and cortisol secretion in 5/5 ACC cultures (IC50: 4.5±0.1 μM). IFN-β reduced cell number in 10/11 (IC50: 83±18 IU/ml) and cortisol secretion in 5/5 ACC cultures (IC50: 7.3±1.5 IU/ml). The effect of IFN-β on cell number included the induction of apoptosis. IFN-β strongly inhibited mRNA expression of STAR, CYP11A1, CYP17A1, and CYP11B1. Mitotane and IFN-β induced an additive inhibitory effect on cell number and cortisol secretion. IGF2 (10 nM) inhibited apoptosis and increased cell number and cortisol secretion. These effects were counteracted by IFN-β treatment. Finally, IFN-β inhibited IGF2 secretion and mRNA expression. In conclusion, IFN-β is a potent inhibitor of ACC cell growth in human primary ACC cultures, partially mediated by an inhibition of the effects of IGF2, as well as its production. The increased sensitivity of ACC cells to mitotane induced by treatment with IFN-β may open the opportunity for combined treatment regimens with lower mitotane doses. The inhibition of the expression of steroidogenic enzymes by IFN-β is a novel mechanism that may explain its inhibitory effect on cortisol production.

Entities:  

Keywords:  adrenocortical carcinoma; insulin-like growth factor 2; interferon receptor; mitotane; type 1 interferons

Mesh:

Substances:

Year:  2013        PMID: 23507702     DOI: 10.1530/ERC-12-0217

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  6 in total

1.  Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

Authors:  Maria Cristina De Martino; Peter M van Koetsveld; Richard A Feelders; Steven W J Lamberts; Wouter W de Herder; Annamaria Colao; Rosario Pivonello; Leo J Hofland
Journal:  Endocrine       Date:  2015-12-08       Impact factor: 3.633

Review 2.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

3.  Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.

Authors:  S G Creemers; P M van Koetsveld; E S R van den Dungen; E Korpershoek; F J van Kemenade; G J H Franssen; W W de Herder; R A Feelders; L J Hofland
Journal:  J Clin Endocrinol Metab       Date:  2016-09-07       Impact factor: 5.958

4.  Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.

Authors:  Teresa Gagliano; Erica Gentilin; Katiuscia Benfini; Carmelina Di Pasquale; Martina Tassinari; Simona Falletta; Carlo Feo; Federico Tagliati; Ettore Degli Uberti; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2014-08-06       Impact factor: 3.633

5.  Two common disease-associated TYK2 variants impact exon splicing and TYK2 dosage.

Authors:  Zhi Li; Maxime Rotival; Etienne Patin; Frédérique Michel; Sandra Pellegrini
Journal:  PLoS One       Date:  2020-01-21       Impact factor: 3.240

Review 6.  The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.

Authors:  Malik Salman Haider; Taufiq Ahmad; Jürgen Groll; Oliver Scherf-Clavel; Matthias Kroiss; Robert Luxenhofer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-21       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.